Cited by 1,817PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase SignalingMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 101 of the 103 references it cites were found in a registry or an index.

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Open access

Mendoza, Michelle C., Er, E. Emrah, Blenis, John·2011·Trends in Biochemical Sciences

DOI 10.1016/j.tibs.2011.03.006PMC PMC3112285

Open this paper in CoChat — free account

Abstract

The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms for controlling cell survival, differentiation, proliferation, metabolism, and motility in response to extracellular cues. Components of these pathways were among the first to be discovered when scientists began cloning proto-oncogenes and purifying cellular kinase activities in the 1980s. Ras-ERK and PI3K-mTOR were originally modeled as linear signaling conduits activated by different stimuli, yet even early experiments hinted that they might intersect to regulate each other and co-regulate downstream functions. The extent of this cross-talk and its significance in cancer therapeutics are now becoming clear.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.tibs.2011.03.006

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,578
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,908
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

Show all 103 references

Sorted by citations

AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,719
Reprogramming of fatty acid metabolism in cancer
Koundouros, N., & Poulogiannis, G. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0650-z · Cited by 1,669
The Transcription Factor TFEB Links mTORC1 Signaling to Transcriptional Control of Lysosome Homeostasis
Roczniak-Ferguson, A., Petit, C. S. V., Froehlich, F., Qian, S., Ky, J., Angarola, B. L., Walther, T. C., & Ferguson, S. M. (2012) · Science Signaling · doi:10.1126/scisignal.2002790 · Cited by 1,393
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Self-citation
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 802
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 652
Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 598
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 602
mTOR complex 2 signaling and functions
Oh, W. J., & Jacinto, E. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16586 · Cited by 597
Using Optogenetics to Interrogate the Dynamic Control of Signal Transmission by the Ras/Erk Module
Toettcher, J. E., Weiner, O. D., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.11.004 · Cited by 539
Ubiquitin ligases in oncogenic transformation and cancer therapy
Senft, D., Qi, J., & Ronai, Z. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.105 · Cited by 499
Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer
Tsay, J.-C. J., Wu, B. G., Badri, M. H., Clemente, J. C., Shen, N., Meyn, P., Li, Y., Yie, T.-A., Lhakhang, T., Olsen, E., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2118oc · Cited by 448
Endoplasmic Reticulum Stress in Malignancy
Clarke, H. J., Chambers, J. E., Liniker, E., & Marciniak, S. J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.015 · Cited by 473
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
Liu, G., Pei, F., Yang, F., Li, L., Amin, A. D., Liu, S., Buchan, J. R., & Cho, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020367 · Cited by 428
Obesity and Cancer Mechanisms: Cancer Metabolism
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9712 · Cited by 425
Stress granules, P-bodies and cancer
Anderson, P., Kedersha, N., & Ivanov, P. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.009 · Cited by 408
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Slomovitz, B. M., & Coleman, R. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0662 · Cited by 411
NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
Chio, I. I. C., Jafarnejad, S. M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.056 · Cited by 378
“Reactivation of EGFR and MAPK (mitogen-activated protein kinase) signaling upon inhibition of AKT is an important adaptive survival response, leading to drug resistance in Kras mutant cancer cells, and requires an intact autocrine EGFR signaling cascade to enact (Mendoza et al., 2011).”
Comparison of cancer cells cultured in 2D vs 3D reveals differences in AKT/mTOR/S6-kinase signaling and drug response
Riedl, A., Schlederer, M., Pudelko, K., Stadler, M., Walter, S., Unterleuthner, D., Unger, C., Kramer, N., Hengstschläger, M., Kenner, L., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.188102 · Cited by 389
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 396
mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1
Morita, M., Prudent, J., Basu, K., Goyon, V., Katsumura, S., Hulea, L., Pearl, D., Siddiqui, N., Strack, S., McGuirk, S., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.08.013 · Cited by 379
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., & Reikvam, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082907 · Cited by 365
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Möbitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 365
Dual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Targeting the PI3-kinase pathway in triple-negative breast cancer
Pascual, J., & Turner, N. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz133 · Cited by 339
Nutrient regulation of mTORC1 at a glance
Condon, K. J., & Sabatini, D. M. (2019) · Journal of Cell Science · doi:10.1242/jcs.222570 · Cited by 342
Growing knowledge of the mTOR signaling network
Huang, K., & Fingar, D. C. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.09.011 · Cited by 310
Selective Insulin and Leptin Resistance in Metabolic Disorders
Könner, A. C., & Brüning, J. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.004 · Cited by 320
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 317
The Circadian Clock Coordinates Ribosome Biogenesis
Jouffe, C., Cretenet, G., Symul, L., Martín, E., Atger, F., Naef, F., & Gachon, F. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001455 · Cited by 294
Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling
Wang, Z. (2021) · Cells · doi:10.3390/cells10123327 · Cited by 316
TSC1 controls macrophage polarization to prevent inflammatory disease
Zhu, L., Yang, T., Li, L., Sun, L., Hou, Y., Hu, X., Zhang, L., Tian, H., Zhao, Q., Peng, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms5696 · Cited by 287
Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Zhai, B., Hu, F., Jiang, X. L., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1043 · Cited by 286
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 292
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T. L., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 299
Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming
Adeshakin, F. O., Adeshakin, A. O., Afolabi, L. O., Yan, D., Zhang, G., & Wan, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626577 · Cited by 277
Nutrient Regulation of the mTOR Complex 1 Signaling Pathway
Kim, S. G., Buel, G. R., & Blenis, J. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0138-2 · Cited by 268
Self-citation
A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Cheng, X. (2024) · Genes · doi:10.3390/genes15070903 · Cited by 258
Mechanistic Target of Rapamycin–Independent Antidepressant Effects of ( R )-Ketamine in a Social Defeat Stress Model
Yang, C., Ren, Q., Qu, Y., Zhang, J., Ma, M., Dong, C., & Hashimoto, K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 254
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapyPreprint
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 259
Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis
Xu, X., Fan, Z., Kang, L., Han, J., Jiang, C., Zheng, X., Zhu, Z., Jiao, H., Lin, J., Jiang, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64265 · Cited by 249
Concepts in Boolean network modeling: What do they all mean?
Schwab, J. D., Werle, S. D., Ikonomi, N., Kühl, M., & Kestler, H. A. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.001 · Cited by 256
Ketamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 266
Mitochondrial sirtuins, metabolism, and aging
Ji, Z., Liu, G., & Qu, J. T. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.11.005 · Cited by 250
Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies
Mäkinen, T., Boon, L. M., Vikkula, M., & Alitalo, K. K. (2021) · Circulation Research · doi:10.1161/circresaha.121.318142 · Cited by 237
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07858-8 · Cited by 224
AKT and ERK dual inhibitors: The way forward?
Cao, Z., Liao, Q., Su, M., Huang, K., Jin, J., & Cao, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.025 · Cited by 244
Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
Magaway, C., Kim, E., & Jacinto, E. (2019) · Cells · doi:10.3390/cells8121584 · Cited by 231
Chemoresistance and targeted therapies in ovarian and endometrial cancers
Brasseur, K., Gévry, N. Y., & Asselin, É. (2016) · Oncotarget · doi:10.18632/oncotarget.14021 · Cited by 230
Innate Immune Programing by Endotoxin and Its Pathological Consequences
Morris, M. C., Gilliam, E. A., & Li, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00680 · Cited by 224
Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling
Lee, G., Zheng, Y., Cho, S., Jang, C., England, C., Dempsey, J. M., Yu, Y., Liu, X., He, L., Cavaliere, P. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.037 · Cited by 229
Self-citation
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 215
Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging
Turi, Z., Lacey, M., Mistrík, M., & Moudrý, P. (2019) · Aging · doi:10.18632/aging.101922 · Cited by 220
Mechanisms and pathways of growth failure in primordial dwarfismPreprint
Klingseisen, A., & Jackson, A. P. (2011) · Genes & Development · doi:10.1101/gad.169037 · Cited by 220
Chemoresistance and the Self-Maintaining Tumor Microenvironment
Yeldag, G., Rice, A. J., & Hernández, A. E. D. R. (2018) · Cancers · doi:10.3390/cancers10120471 · Cited by 222
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
Purba, E. R., Saita, E., & MARUYAMA, I. N. (2017) · Cells · doi:10.3390/cells6020013 · Cited by 218
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Li, H., Zeng, J., & Shen, K. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3377-3 · Cited by 206
Targeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 213
Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A
Fledrich, R., Stassart, R. M., Klink, A., Rasch, L. M., Prukop, T., Haag, L. M., Czesnik, D., Kungl, T., Abdelaal, T. A., Keric, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3664 · Cited by 196
Translational control of stem cell function
Saba, J. A., Liakath‐Ali, K., Green, R., & Watt, F. M. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00386-2 · Cited by 205
mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions
Showkat, M., Beigh, M. A., & Andrabi, K. I. (2014) · Molecular Biology International · doi:10.1155/2014/686984 · Cited by 196
MEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 198
mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis
Villa, E., Sahu, U., O’Hara, B. P., Ali, E. S., Helmin, K. A., Asara, J. M., Gao, P., Singer, B. D., & Ben‐Sahra, I. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.009 · Cited by 194
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka, M., Li, Y., Sukari, A., Ou, S.-H. I., Al-Hallak, M. N., & Azmi, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101974 · Cited by 185
The Hallmarks of Flavonoids in Cancer
Ponte, L. G. S., Pavan, I. C. B., Mancini, M. C. S., da Silva, L. G. S., Morelli, A. P., Severino, M. B., Bezerra, R. M. N., & Simabuco, F. M. (2021) · Molecules · doi:10.3390/molecules26072029 · Cited by 188
Impaired insulin signalling and allostatic load in Alzheimer disease
Felice, F. G. D., Gonçalves, R. A., & Ferreira, S. T. (2022) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00558-9 · Cited by 183
The effects of metformin on autophagy
Lu, G., Wu, Z., Shang, J., Xie, Z., Chen, C., & zhang, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111286 · Cited by 188
Brain-Derived Neurotrophic Factor (BDNF): Novel Insights into Regulation and Genetic Variation
Notaras, M. J., & van den Buuse, M. (2018) · The Neuroscientist · doi:10.1177/1073858418810142 · Cited by 184
Extracellular Signal-Regulated Kinase: A Regulator of Cell Growth, Inflammation, Chondrocyte and Bone Cell Receptor-Mediated Gene Expression
Lu, N., & Malemud, C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153792 · Cited by 178
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives
Pouysségur, J., Marchiq, I., Parks, S. K., Durivault, J., Ždralević, M., & Vučetić, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.004 · Cited by 178
Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia
Bicocca, V. T., Chang, B. H., Masouleh, B. K., Müschen, M., Loriaux, M., Druker, B. J., & Tyner, J. W. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.027 · Cited by 171
Shock Wave Treatment Enhances Cell Proliferation and Improves Wound Healing by ATP Release-coupled Extracellular Signal-regulated Kinase (ERK) Activation
Weihs, A. M., Fuchs, C., Teuschl, A., Hartinger, J., Slezak, P., Mittermayr, R., Redl, H. R., JUNGER, W. G., Sitte, H. H., & Rünzler, D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.580936 · Cited by 173
Insulin Resistance and Cancer: In Search for a Causal Link
CHIEFARI, E. D., Mirabelli, M., Vignera, S. L., Tanyolaç, S., FOTI, D. P., Aversa, A., & Brunetti, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011137 · Cited by 180
Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting
Knight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Wei, W., Shin, Y. S., Xue, M., Matsutani, T., Masui, K., Yang, H., Ikegami, S., Gu, Y., Herrmann, K., Johnson, D., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.012 · Cited by 172
Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations
Osborn, A. J., Dickie, P., Neilson, D., Glaser, K., Lynch, K. A., Gupta, A., & Dickie, B. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu505 · Cited by 166
PGE2 activates EP4 in subchondral bone osteoclasts to regulate osteoarthritis
Jiang, W., Jin, Y., Zhang, S., Ding, Y. G., Huo, K., Yang, J., Жао, Л., Nian, B., Zhong, T. P., Lü, W., et al. (2022) · Bone Research · doi:10.1038/s41413-022-00201-4 · Cited by 176
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives
Khatoon, E., Banik, K., Harsha, C., Sailo, B. L., Thakur, K. K., Khwairakpam, A. D., Vikkurthi, R., Devi, T. B., Gupta, S. C., & Kunnumakkara, A. B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.014 · Cited by 163
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 166
Targeting cancer by binding iron: Dissecting cellular signaling pathways
Lui, G. Y. L., Kovačević, Ž., Richardson, V., Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2015) · Oncotarget · doi:10.18632/oncotarget.4349 · Cited by 165
Engineering an Artificial T‐Cell Stimulating Matrix for Immunotherapy
Hickey, J. W., Dong, Y. W., Chung, J. W., Salathe, S. F., Pruitt, H. C., Li, X., Chang, C. K. W., Fraser, A. K., Bessell, C. A., Ewald, A. J., et al. (2019) · Advanced Materials · doi:10.1002/adma.201807359 · Cited by 156
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., Ottaviano, V., & Queirolo, P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s39096 · Cited by 163
Diagnostic Pathology of Tumors of Peripheral Nerve
Belakhoua, S., & Rodríguez, F. J. (2021) · Neurosurgery · doi:10.1093/neuros/nyab021 · Cited by 160
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
Alain, T., Morita, M., Fonseca, B. D., Yanagiya, A., Siddiqui, N., Bhat, M., Zammit, D., Marcus, V., Metrakos, P. P., Voyer, L.-A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2395 · Cited by 165
Benefits of Lactoferrin, Osteopontin and Milk Fat Globule Membranes for Infants
Demmelmair, H., Prell, C., Timby, N., & Lönnerdal, B. L. (2017) · Nutrients · doi:10.3390/nu9080817 · Cited by 160
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Felsenstein, K. M., & Theodorescu, D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.179 · Cited by 159
The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer
Vallejo-Díaz, J., Chagoyen, M., Olazabal-Morán, M., González-Garcı́a, A., & Carrera, A. C. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.009 · Cited by 158
Crosstalk in Cellular Signaling: Background Noise or the Real Thing?
Vert, G., & Chory, J. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.11.006 · Cited by 154
The immunobiology of mTOR in autoimmunity
Suto, T., & Karonitsch, T. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102373 · Cited by 149
Cationic, anionic and neutral polysaccharides for skin tissue engineering and wound healing applications
Nosrati, H., Khodaei, M., Alizadeh, Z., & Banitalebi-Dehkordi, M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.013 · Cited by 155
Multi-omic Profiling Reveals Dynamics of the Phased Progression of Pluripotency
Yang, P., Humphrey, S. J., Cinghu, S., Pathania, R., Oldfield, A. J., Kumar, D., Perera, D., Yang, J. Y. H., James, D. E., Mann, M., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.012 · Cited by 146
Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis
Flex, E., Jaiswal, M., Pantaleoni, F., Martinelli, S., Strullu, M., Fansa, E. K., Caye‐Eude, A., Luca, A. D., Lepri, F. R., Dvorský, R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu148 · Cited by 145
The Landscape of Atypical and Eukaryotic Protein Kinases
Kanev, G. K., de Graaf, C., de Esch, I. J. P., Leurs, R., Würdinger, T., Westerman, B. A., & Kooistra, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.002 · Cited by 143
Reviewing the Effects of l-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis
Pedroso, J. A. B., Zampieri, T. T., & Donato, J. (2015) · Nutrients · doi:10.3390/nu7053914 · Cited by 160
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 141
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
Nguyen, T. V., Sleiman, M., Moriarty, T., Herrick, W. G., & Peyton, S. R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.058 · Cited by 142
mTOR signaling response to resistance exercise is altered by chronic resistance training and detraining in skeletal muscle
Ogasawara, R., Kobayashi, K., Tsutaki, A., Lee, K., Abe, T., Fujita, S., Nakazato, K., & Ishii, N. (2013) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01161.2012 · Cited by 138

Authors: Mendoza, M. C., Er, E. E., & Blenis, J.
Affiliations: Harvard University (US)
Corresponding author: Blenis, John
ORCID: Mendoza, Michelle C.
Er, E. Emrah
Blenis, John
Venue: Trends in Biochemical Sciences
Publisher: Elsevier BV
Published: 2011-06
Volume: 36
Issue: 6
Pages: 320-328
ISSN: 0968-0004 (ISSN-L)
DOI: 10.1016/j.tibs.2011.03.006
PMC: PMC3112285
OpenAlex: W1998203489
Cited by: 1,817
References: 103
Citations by year: 2026: 112 · 2025: 96 · 2024: 122 · 2023: 133 · 2022: 127 · 2021: 163 · 2020: 166 · 2019: 164 · 2018: 144 · 2017: 158 · 2016: 123 · 2015: 100 · 2014: 92 · 2013: 55 · 2012: 49
FWCI: 5.82
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Trends in Biochemical Sciences (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: LAM Foundation
Susan G. Komen
National Cancer Institute (R37CA046595)
National Institute of General Medical Sciences (R01GM051405)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: Ras/ERK signaling pathway, signaling crosstalk, cell survival, cell proliferation, cell differentiation, cellular metabolism, cell motility, proto-oncogenes, cancer therapeutics
MeSH terms: Humans, Signal Transduction, ras Proteins, Extracellular Signal-Regulated MAP Kinases, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks